Efficacy and Safety of Rifaximin With NAC in IBS-D
Status:
Active, not recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
Randomized, prospective proof of concept, double-blind, single site clinical trial to
determine the efficacy of combined rifaximin and N-acetylcysteine (NAC) therapy vs. rifaximin
alone in decreasing clinical symptoms in subjects with IBS-D.